The American Society of Clinical Oncology has issued a position statement in the Journal of Clinical Oncology, calling for federal agencies and the cancer research community to broaden clinical trials to include older adults.
The American Society of Clinical Oncology (ASCO) has issued a position statement in the Journal of Clinical Oncology, calling for federal agencies and the cancer research community to broaden clinical trials to include older adults. ASCO also called for redefining eligibility for clinical trials. Despite being a fast-growing segment of the population within the United States, older adults are not well represented in clinical trials (CTs). Additionally, similar to pediatric trials, very few CTs are specifically designed for older adults, and physicians develop their treatment plans by extrapolating results obtained from the healthier, younger population.
The result? Lack of accurate toxicity data and absence of knowledge on age-appropriate trial end points.
With the position statement, ASCO makes 5 recommendations that can improve evidence-generation in the older population:
“Older people living with cancer often have different experiences and outcomes in their treatment than younger cancer patients,” said ASCO President Julie M. Vose, MD, MBA, FASCO. “As we age, for example, the risk of adverse reactions from treatment significantly increases. Older adults must be involved in clinical trials so we can learn the best way to treat older cancer patients resulting in improved outcomes and manageable toxicity.”
Read the press release here: http://bit.ly/1fhRGY4
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
The Joint Commission is launching the Rural Health Clinic Accreditation Program to standardize staff training and patient care practices at rural health clinics nationwide; the American Cancer Society recently launched the largest-ever study of cancer risk and outcomes in Black women; the HHS COVID-19 vaccination campaign saved $732 billion by preventing illness and related costs.
Read More
Budesonide-Based Triple Therapy Shows Best Benefit Over Dual Therapy for COPD
May 8th 2024The triple therapy of budesonide, glycopyrrolate, and formoterol fumarate showed the greatest incremental net benefit among a series of triple therapy medications that were evaluated against dual therapy for chronic obstructive pulmonary disease (COPD), according to an analysis presented at ISPOR.
Read More